Suppr超能文献

相似文献

1
Emerging therapeutic targets for sepsis.
Expert Opin Ther Targets. 2021 Mar;25(3):175-189. doi: 10.1080/14728222.2021.1897107. Epub 2021 Apr 12.
2
Sepsis Care Pathway 2019.
Qatar Med J. 2019 Nov 7;2019(2):4. doi: 10.5339/qmj.2019.qccc.4. eCollection 2019.
3
Epigenetic coordination of acute systemic inflammation: potential therapeutic targets.
Expert Rev Clin Immunol. 2014 Sep;10(9):1141-50. doi: 10.1586/1744666X.2014.943192. Epub 2014 Aug 4.
4
Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis.
Expert Rev Clin Immunol. 2017 Sep;13(9):907-919. doi: 10.1080/1744666X.2017.1357469. Epub 2017 Jul 28.
5
Evolving Paradigms in Sepsis Management: A Narrative Review.
Cells. 2024 Jul 9;13(14):1172. doi: 10.3390/cells13141172.
6
Sepsis in the critically ill patient: current and emerging management strategies.
Expert Rev Anti Infect Ther. 2021 May;19(5):635-647. doi: 10.1080/14787210.2021.1846522. Epub 2020 Nov 23.
7
The immune system's role in sepsis progression, resolution, and long-term outcome.
Immunol Rev. 2016 Nov;274(1):330-353. doi: 10.1111/imr.12499.
8
Novel approaches to the development of anti-sepsis drugs.
Expert Opin Drug Discov. 2014 May;9(5):523-31. doi: 10.1517/17460441.2014.905538. Epub 2014 Apr 3.
9
The future of Cochrane Neonatal.
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
10
Proteomics and systems biology approaches to signal transduction in sepsis.
Crit Care Med. 2003 Jan;31(1 Suppl):S1-6. doi: 10.1097/00003246-200301001-00001.

引用本文的文献

2
Pro-Dermcidin as an Emerging Regulator of Innate Immunity in Sepsis.
Int J Mol Sci. 2025 Aug 7;26(15):7643. doi: 10.3390/ijms26157643.
3
Combined Analysis of Transcriptome and Mendelian Randomization Reveals and as Biomarkers Related to Glucose Metabolism in Sepsis.
J Inflamm Res. 2025 Jul 30;18:10213-10234. doi: 10.2147/JIR.S528347. eCollection 2025.
4
Dopamine as an endogenous regulator of innate immunity in sepsis.
Front Immunol. 2025 Jul 9;16:1625368. doi: 10.3389/fimmu.2025.1625368. eCollection 2025.
6
Pro-dermcidin and derivatives as potential therapeutics for lethal experimental sepsis.
Front Immunol. 2025 Jun 4;16:1621633. doi: 10.3389/fimmu.2025.1621633. eCollection 2025.
7
Molecular Biomarkers and More Efficient Therapies for Sepsis.
Biomedicines. 2025 Feb 14;13(2):468. doi: 10.3390/biomedicines13020468.
8
Connexin 43 and Pannexin 1 hemichannels as endogenous regulators of innate immunity in sepsis.
Front Immunol. 2024 Dec 23;15:1523306. doi: 10.3389/fimmu.2024.1523306. eCollection 2024.

本文引用的文献

1
An in vivo atlas of host-pathogen transcriptomes during colonization and disease.
Proc Natl Acad Sci U S A. 2020 Dec 29;117(52):33507-33518. doi: 10.1073/pnas.2010428117. Epub 2020 Dec 14.
2
Unmasking Unique Immune Altering Aspects of the Microbiome as a Tool to Correct Sepsis-Induced Immune Dysfunction.
Surg Infect (Larchmt). 2021 May;22(4):400-408. doi: 10.1089/sur.2020.233. Epub 2020 Sep 30.
3
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
Science. 2020 Aug 21;369(6506):1010-1014. doi: 10.1126/science.abd0827. Epub 2020 Jun 15.
4
Remdesivir for the Treatment of Covid-19 - Final Report.
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
9
A pneumonia outbreak associated with a new coronavirus of probable bat origin.
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验